ImmunoGen and Merck have entered into a clinical research collaboration to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), for the treatment of patients with FRα-positive ovarian cancer.   Mirvetuximab soravtansine, a monoclonal antibody, enables it to bind to FRα-positive tumor cells with ImmunoGen’s DM4, a maytansinoid cancer-killing agent, to kill these cells. In preclinical research conducted by ImmunoGen, ADCs with mayt...